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Abstract 
Metformin is the first line treatment for type 2 diabetes (T2D). Although widely prescribed, the glucose-
lowering mechanism for metformin is incompletely understood. Here we used a genome-wide 
association approach in a diverse group of individuals with T2D from the Action to Control 
Cardiovascular Risk in Diabetes (ACCORD) clinical trial to identify common and rare variants associated 
with HbA1c response to metformin treatment, and followed up these findings in four replication 
cohorts. Common variants in PRPF31 and CPA6, were associated with worse and better metformin 
response, respectively (p<5x10-6), and meta-analysis in independent cohorts displayed similar 
associations with metformin response (p=1.2x10-8 and p=0.005, respectively). Previous studies have 
shown that PRPF31(+/-) knockout mice have increased total body fat (p=1.78x10-6) and increased fasted 
circulating glucose (p=5.73x10-6). Furthermore, rare variants in STAT3 associated with worse metformin 
response(q<0.1). STAT3 is a ubiquitously expressed pleiotropic transcriptional activator that participates 
in the regulation of metabolism and feeding behavior. Here we provide novel evidence for associations 
of common and rare variants in PRPF31, CPA6, and STAT3 with metformin response that may provide 
insight into mechanisms important for metformin efficacy in T2D.  
Introduction 
 The incidence of Type 2 Diabetes (T2D) is increasing and the Centers for Disease Control and 
Prevention estimate that 11% of U.S. adults, aged 20 years or older, have diagnosed or undiagnosed 
T2D, and 35% of people in the same age group have prediabetes based on fasting glucose or hemoglobin 
A1c (HbA1c) levels(1). T2D is now considered a global epidemic with prevalence increasing from 108 
million in 1980 to 422 million in 2014(2). Individuals with T2D are at an increased risk of developing 
blindness and kidney failure, and are at risk for lower limb amputations. Furthermore, individuals with 
T2D are 2-4x more likely to develop cardiovascular disease (CVD), including heart attack and stroke(3).   
 Metformin, a member of the biguanide class of drugs, is now considered first line therapy for 
individuals with T2D(4). Despite intensive investigation, the molecular mechanisms mediating 
metformin’s beneficial effects on glycemic control remain controversial and poorly understood. Studies 
performed predominantly in animal models have implicated various mechanisms and molecules as 
participating in metformin’s beneficial effects, including direct inhibitory effects on mitochondrial 
function, activation of hepatic AMPK, and alterations in glucagon signaling pathways(5–10). The relative 
importance of these mechanisms for metformin’s beneficial effects on glycemic control in humans is 
unclear.  
There is significant inter-individual variability in response to metformin(11–13).  This suggests that a 
better understanding of the mechanisms by which metformin functions might allow for more tailored 
and precise treatment. Studies suggest that heritable factors contribute to this variability, which 
provides an opportunity to identify causal genetic contributors through genetic association studies(11). 
Recent GWAS have identified common variants that affected metformin response in the ATM locus, 
which has been shown to activate AMPK, and the SLC2A2 locus, which encodes the facilitated glucose 
transporter, GLUT2(12,13). Here we use a GWAS approach in a large cohort of individuals with T2D in 
the ACCORD clinical trial to test for associations of both common and rare variant SNPs with change in 
HbA1c in response to metformin treatment. 
 The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial followed 10,251 
participants for up to 8 years at 77 clinical centers in the United States and Canada to compare the 
benefits and risks of treatment strategies for intensively targeting glycemia, blood pressure, and 
dyslipidemia versus standard targets in individuals with T2D at high risk for CVD(14–17). No overall 
benefit and possible harms were observed in the combined primary CVD endpoints with intensive 
glucose-lowering therapy.  However, significant variability in treatment response was also observed, 
highlighting the potential for identifying genetic markers of drug response that may lead to the 
development of improved and personalized treatment strategies. The results presented here point to 
novel mechanisms of metformin drug response and potential therapeutic targets for the treatment of 
T2D.  
Research Design and Methods 
Study Participants 
 The ACCORD trial (clinicaltrials.gov-NCT00000620) was a double 2x2 factorial design comparing 
intensive versus standard treatment approaches for controlling glycemia, blood pressure, and 
dyslipidemia that enrolled 10,251 patients with T2D with a history of CVD or at least two known risk 
factors for CVD, such as documented atherosclerosis, albuminuria, dyslipidemia, hypertension, smoking, 
or obesity(14). Additional details about randomization and selection criteria for the various arms of the 
ACCORD trial can be found in the Supplemental Material. Participants in ACCORD were given an option 
to provide a blood sample for future genetic studies, and over 80% of participants agreed to do so. A 
workflow describing the selection of subjects can be found in Figure 1. Additional demographic 
information can be found in Table 1. 
Phenotype Definitions 
Glycemic response to metformin was evaluated in subjects who began taking metformin while enrolled 
in ACCORD; subjects who reported taking metformin or another biguanide prior to enrollment in the 
trial were excluded. Some subjects were taking additional medications and were accounted for as 
described in the Supplemental Material and Graham and Rotroff et al.(18). Subjects were scheduled for 
study visits every 1 or 4 months based on randomization to the intensive or standard glycemia arms, 
respectively.  HbA1c was recorded every 4 months. Metformin response was calculated as on-treatment 
HbA1c minus pre-treatment HbA1c. Pre-treatment HbA1c levels were recorded no more than 30 days 
prior to the start of metformin. On-treatment HbA1c levels were defined as the first recorded 
measurement acquired after at least 90-days and no more than 270-days from the start of metformin 
treatment. This interval was chosen to allow for HbA1c levels to stabilize after starting metformin, while 
limiting changes in glycemia levels due to additional modifications to treatment regimens. Medication 
compliance and other details regarding the phenotype definition can be found in the Supplemental 
Material.  
Genotyping 
Briefly, 6,085 unique samples from ACCORD participants who consented to genetic studies 
conducted by any investigator, were genotyped at the University of Virginia on Illumina 
HumanOmniExpressExome-8 v1.0 chips (Set 1); 8,174 unique samples, including the above 6,085 
samples plus 2,089 samples from ACCORD participants who consented to genetic studies only if 
conducted by ACCORD investigators, were genotyped at the University of North Carolina on Affymetrix 
Axiom Biobank1 chips (Set 2). The data were then merged, resulting in one dataset consisting of 5,971 
samples genotyped at a total of 1,240,656 individual SNPs, and an additional 2,083 samples genotyped 
at 583,613 SNPs. Additional details can be found in the Supplementary Material and Marvel and Rotroff 
et al.(19).  
Data Processing 
Covariate Selection 
We implemented a variable selection procedure to address potential confounding. Some 
variables were included in the model based on previous studies or expert knowledge, while other 
variables were selected based on a backwards selection approach and Bayesian information criteria to 
identify covariates specific to the ACCORD dataset. All covariate names and descriptions before variable 
selection can be found in Supplemental Table 1. A substantial proportion of the cohort was taking other 
medications during the metformin treatment response time frame and these concomitant medications 
were incorporated into the model as described in the Supplementary Material. To prevent confounding 
due to population substructure, principal component analysis (PCA) was performed based on the 
genotype data using EIGENSTRAT (v4.2), and is described in the Supplemental Material. The final models 
after covariate selection can be found in Supplementary Tables 2-4. A workflow detailing each step of 
the analysis can be found in Supplemental Figure 4. 
Common Variant Analysis 
 Associations between a phenotype, covariates, and single common variant (MAF>3%) were 
tested using the linear regression model. Genotyped variants were tested as an additive variable using 
PLINK, where 𝑔𝑖 ∈ {0,1,2} is the number of minor alleles for the 𝑖
th individual. Imputed variants were 
tested using a linear regression model in the statistical programming language, R, where 𝑔𝑖 = 𝑝𝑖(𝐴𝑎) +
2𝑝𝑖(𝑎𝑎) is the dosage score computed from the posterior probabilities for genotypes 𝐴𝑎 and 𝑎𝑎 (20). 
For SNPs that were only genotyped in Set 1 subjects and were imputed in Set 2 subjects, association 
tests were calculated for each set separately and the results were combined by meta-analysis using 
PLINK(21,22). Tables and figures specify whether each result derives from a SNP that was genotyped in 
all subjects, imputed in all subjects, or represents a combination of genotyped and imputed data using 
the meta-analysis approach described.   
Rare Variant Analysis 
The rare variant analysis approach has been previously described(19). Briefly, all variants 
(MAF3%) were mapped to gene annotation from Ensemble (GRCh37.p13). A suite of five rare variant 
tests comprised of burden and non-burden were then used to assess associations with metformin 
response. We combined the set of five p-values from each test into a single p-value for each gene using 
the procedure described by Dai et al.(23). Subsequently, the combined p-value was corrected for 
multiple comparisons with a false discovery rate approach(24,25), and a threshold of q<0.1 was used for 
statistical significance.  
Replication of ACCORD Results 
SNPs that associated with metformin response in the common variant analyses (p<5x10-6) were 
tested for associations in the following cohorts: There was one cohort from European ancestry, which 
included combined samples from  Genetics of Diabetes Audit and Research in Tayside Scotland 
(GoDARTS) and PMET1-EU (REP1) (n=6963).  There were two cohorts from African American ancestry, 
referred to as REP2 (n=646) and REP3 (n=369). Briefly, the GoDARTS cohort in REP1 has been described 
before by WTCCC2(13). The REP2 cohort was collected from two main clinical sites, Kaiser Permanente 
Northern California and Kaiser Permanente South East, as previously described(26). The PMET1-EU in 
REP1 and the REP3 cohorts were collected from The Research Program on Genes, Environment, and 
Health (RPGEH), based at Kaiser Permanente Northern California(27). Metformin response for REP1 was 
defined as pre-treatment HbA1c minus post-treatment HbA1c, resulting in effects that are in the 
opposite direction of those in ACCORD. Because of this, the additive inverse of effect sizes in REP1 were 
used in the analysis with ACCORD results.  For REP2 and REP3, metformin response was calculated as 
post–treatment HbA1c minus pre–treatment HbA1c.  
To provide additional support for the role of the lead SNP, rs57081354, in modulating 
metformin action, we performed an association test between rs57081354 and baseline HbA1c in 
ACCORD individuals that were already on metformin at the start of the trial (REP4) and compared those 
results to the association of baseline HbA1c in individuals not on metformin at the start of the trial. All 
individuals in REP4 were excluded from the discovery cohort due to the lack of a recorded pre-treatment 
HbA1c, making it impossible to calculate a change in HbA1c upon treatment. For this analysis, an 
association test was performed as described in the common variant analysis section described above 
with the exception of the phenotype being baseline level of HbA1c rather than change in HbA1c.  
Each SNP with p<5x10-8 in the discovery cohort, or with p<5x10-6 in the discovery cohort and 
q<0.01 in at least one replication cohort, were meta-analyzed across available cohorts using 
PLINK(21,22). Meta-analysis with p<0.05 was considered to be statistically significant. Additional 
information regarding each cohort can be found in the Supplemental Material and a workflow 
describing how the replication was evaluated can be found in Supplemental Figure 4.  
Dietary Analysis 
Dietary questionnaires were assessed for 1600 participants that both consented to genotyping 
and had dietary records as part of the Health-Related Quality of Life Substudy within ACCORD. Scores in 
response to the dietary questionnaires were tested for association with the lead SNP, rs57081354, using 
a linear regression model and the same covariate selection process as described above. Details 
regarding this analysis can be found in the Supplemental Material.     
Results 
A total of 1312, 845, and 222 subjects were included in the common and rare variant analyses 
for all races combined, white, and black cohorts, respectively (Figure 1). Other racial groups were 
included in the all races combined group, but sample sizes were too small to perform stratified analyses. 
Variation was observed in HbA1c response (Figure 2). The mean change in HbA1c was -1.42% (95% CI -
1.49, -1.36) for all races combined, -1.47% (95 %CI -1.55, -1.39) for white subjects only, and -1.35% (95% 
CI -1.50, -1.19) for black subjects only. The difference in the change in HbA1c between white and black 
subjects was not statistically significant(p=0.16). Variables selected as being significantly associated with 
metformin response explained approximately 55% of the variation in metformin response, and were 
subsequently included in the common and rare variant analyses (Supplementary Tables 2-4). Briefly, 
assignment to the intensive glycemia arm of the ACCORD trial, years with T2D, and pre-treatment HbA1c 
were significantly associated with metformin response in all tested groups.  
Common Variant Analysis 
A total of 316,203 genotyped, 547,639 meta-analyzed, and 7,567,403 imputed variants had 
MAF>3% and were included in the common variant analysis when all races were combined. A total of 1, 
3, 7 SNPs were significantly associated with HbA1c response in all races combined, white subjects only, 
and black subjects only, respectively (p<5x10-8). In all subjects combined, the lead SNP rs57081354 
located within an intron in the NBEA gene associated with HbA1c response (Figure 3). 65 SNPs in 16 loci 
on 14 different chromosomes (in genes: NBEA, LOC105374140, CXCL13, MCC, FAM189A1, 
LOC107984525, LOC105379109, KIAA1024, RBFOX1, LOC643339, UBOX5, NR2C1, BPHL, PRPF31, 
LOC105377165, ADAMTS9-AS2) reached the threshold for suggestive significance (p<5x10-6). For white 
subjects only, 3 SNPs in KIAA1024 were associated with HbA1c response at genome-wide levels of 
significance (p<5x10-8), and 23 SNPs in 7 loci (in genes: KIAA1024, LOC283177, LOC105377165, 
ADAMTS9-AS2, CPA6, NR2C1, DPYD) reached the threshold for suggestive significance (p<5x10-6) 
(Supplementary Figure 1). When black subjects were analyzed separately, 2 SNPs in the LOC102724874 
locus were associated with HbA1c response at genome-wide levels (p<5x10-8), and 53 SNPs in 8 loci (in 
genes: LOC102724874, LOC105374308, LOC105369406, SLC35D3, RHPN2, ETS1, SDK2, GPC6) reached 
the threshold for suggestive significance (p<5x10-6) (Supplementary Figure 2). Lead SNPs associated with 
HbA1c response (p<5x10-6) are presented in Tables 2-4. 
Rare Variant Analysis 
Rare variants (MAF.03) in a total of 17,078 genes were tested for association with HbA1c in all 
subjects combined, and separately in white and black subjects. In the combined subjects’ analysis, rare 
variants in STAT3 were significantly associated with HbA1c response (q<0.1) (Supplementary Figure 3). 
Five rare variants were available for testing in STAT3: rs146620441 (monomorphic), rs140604473 
(missense), rs149214040 (missense), rs114401618 (intronic), and rs17882069 (synonymous) (28). 
Importantly, these four SNPs only showed variation in black subjects, although there were no 
statistically significant rare variant associations observed in race-based analyses (q>0.2). We tested 
whether STAT3 failed to yield significant associations in the stratified analysis due to the small number 
of black subjects (n=222) by oversampling black subjects until we had the same number of subjects as 
when all races were combined (n=1312).  Oversampling to build a larger cohort resulted in a q=0.0016 
versus a q=1 in the original cohort of black subjects, supporting the premise that this rare variant finding 
is relevant for black subjects even though it was detected when all subjects were combined due to an 
increase in statistical power.  
Association with Dietary Phenotypes 
NBEA has been previously reported to influence sugary food preference in animal models(29), and we 
further assessed whether the lead SNP in this locus, rs57081354, was associated with dietary scores.  
Data was available in 1553 ACCORD subjects (Table S6). The C-allele in rs57081354 that associated with 
worse metformin effect also associated with increased consumption of dessert (q=0.12). Subjects with 
the C-allele in rs57081354 were more likely to answer ‘Yes’ to the question, “Did you eat dessert?”, 
within past three months (=0.044, 95% CI= 0.012-0.075).  
Replication 
A total of 134 unique SNPs were associated with metformin response (p<5x10-6) when all races 
were combined, in white subjects only, or in black subjects only. Of these SNPs, 81, 64, and 61 were 
available in REP1, REP2, and REP3 cohorts, respectively. The most significant finding in the discovery 
cohort was rs57081354 located in the NBEA gene (p=4.02x10-8, =0.323). This finding did not replicate in 
REP1 (p>0.05), and was not available for testing in REP2 or REP3. Out of the 26 SNPs in NBEA with 
p<1x10-6, only rs1337379 was tested in REP2 and REP3, but was not associated with metformin response 
(p>0.05). SNPs in NBEA were not significantly associated with metformin response in ACCORD when 
black or white subjects were tested separately, only when all races were combined. Interestingly, in the 
set of subjects who were already on metformin when they enrolled in ACCORD (REP4), rs57081354, was 
marginally associated with higher baseline HbA1c (p=0.09), whereas rs57081354 was not associated 
with baseline variation in HbA1c in those not on metformin (p=0.63). Although the phenotypes for REP1 
and REP4 are not identical, meta-analysis of the ACCORD discovery cohort with REP1 and REP4 produced 
an association representing higher HbA1c on metformin (p=0.009)(Figure 3). 
 In ACCORD, rs254271, located in an intron in Pre-MRNA Processing Factor 31 (PRPF31), was 
associated with worse metformin response when all races were combined (p=3.79x10-6).  In the REP1 
cohort, rs254271 was associated with worse metformin response when corrected for baseline HbA1c 
(p=6.21x10-5) and without adjusting for baseline HbA1c(p=1.57x10-2).  Genotypes for rs254271 were not 
available for analysis in the African American replication cohorts, REP2 and REP3. Meta-analysis of 
ACCORD with REP1 produced a significant association for rs254271 with worse metformin response 
(p=1.2x10-8) (Figure 4). 
In white subjects in ACCORD, rs2162145, located in Carboxypeptidase A6 (CPA6), was associated 
with better metformin response (p=4.04x10-6). This finding was consistent with findings in African 
American subjects in REP2 (p=0.006). Although, rs2162145 was not significantly associated with 
metformin response in black subjects in ACCORD (p=0.14), it is possible that we were underpowered to 
detect an association due to the relatively small number of black subjects available (n=222), and that 
meta-analysis could increase statistical power through the inclusion of additional subjects. Meta-analysis 
of black subjects in ACCORD and those in REP2 and REP3 demonstrated the most significant association 
of rs2162145 with better metformin response (p=0.005) compared to meta-analysis of all white subjects 
(ACCORD white subjects and REP1) and all cohorts (ACCORD, REP1-3) with p=0.22 and p=0.09, 
respectively (Figure 4).  
Discussion 
T2D adversely affects the quality of life for millions of individuals and places a significant burden on 
the health care system in the United States and globally (30,31). Although many treatment options for 
T2D are available, metformin has remained the first-line treatment for T2D for decades. Nevertheless, 
the mechanisms by which metformin lowers blood glucose are not well-understood, and factors that 
may predict which patients will have optimal responses to metformin are also not well-understood. 
Here we use a GWAS approach in a large cohort of individuals with T2D in the ACCORD clinical trial to 
test for both common and rare variant SNPs that associate with change in HbA1c level in response to 
metformin treatment. To support our initial findings, we explored these associations in multiple 
independent cohorts. 
A previous study conducted in a large cohort using electronic medical records (EMR) found that 
African-American patients on metformin had a larger reduction in HbA1c than European Americans(32). 
We failed to find a significant difference between metformin response in white subjects and black 
subjects in ACCORD with changes in HbA1c of -1.47% and -1.35%, respectively (p=0.16). It is possible 
that enrollment in a more structured clinical trial impacts these outcomes differently than the far less 
structured care reflected in EMR data. Additional research will be needed to definitely characterize the 
response of metformin across ethnicities. Previous GWAS have identified rs11212617 in the ATM locus, 
and rs8192675 in SLC2A2 as being significantly associated with metformin response(12,13). However, 
neither SNP was significantly associated with metformin response here (p>0.1).  These SNPS may have 
failed to replicate in the current study due to cohort differences and in particular, the sample size of the 
ACCORD cohort and the use of concomitant medications.  Information regarding the prescribed dose for 
metformin was not recorded in ACCORD and may have impacted our findings. However, as described in 
the methods, we sought a minimal time window to assess the response of metformin while limiting the 
likelihood of other medication changes. Additional details about how these studies compare to ACCORD 
can be found in the Supplemental Material.  
In the analysis of subjects from all racial groups combined (n=1312) (Figure 1), those with the C-
allele of rs254271, an intronic variant in PRPF31, had a worse metformin response at suggestive 
significance levels (p=3.79x10-6 =0.16). The effect of this variant was also observed in REP1, consisting 
of subjects of European ancestry (p=6.21x10-5, = -0.073). Interestingly, rs254271, is an expression 
quantitative trait locus in several tissues for PRPF31 and nearby genes, including NADH:Ubiquinone 
oxidoreductase, NDUFA3, which codes for a subunit of the Complex I of the respiratory chain(33–35). 
Metformin is known to inhibit Complex I of the respiratory chain to cause AMPK activation(5).  In 
addition, previous studies have shown that PRPF31(+/-) knockout mice have increased total body fat 
(p=1.78x10-6) and increased fasted circulating glucose (p=5.73x10-6)(36). 
Genotypes for rs254271 were not available for analysis in the African American replication cohorts, 
REP2 and REP3. The phenotype in REP1 represents HbA1c reduction, so the direction of the effect for 
rs254271 is consistent between ACCORD and REP1, and represents worse HbA1c response in individuals 
with the C allele (Figure 4). Mutations in PRPF31 have been associated with an autosomal dominant rare 
Mendelian disease, retinitis pigmentosa(37). PRPF31 was previously identified as a candidate gene for 
diabetic retinopathy, in a genome-wide linkage study in Mexican-Americans with T2D(38). We tested 
rs254271 for association with eye disorders in ACCORD, however, no significant associations were found 
(p>0.05)(data not shown). Further research will be needed to determine what role SNPs in PRPF31 may 
have in metformin drug response or in diabetic retinopathy. 
In the analysis of only white subjects in ACCORD, rs2162145, in the CPA6 gene, was associated with 
metformin response at suggestive significance levels (p=4.04x10-6 = -0.197). This same SNP was 
associated with metformin response in the REP2 cohort = -0.127), but not in REP1 or REP3 
(p>0.05) (Figure 4). To our knowledge, SNPs in CPA6 have not previously been associated with 
metformin response, however, rs2162145 has a weak significant association with fasting glucose 
(p=0.02)(39). In addition, a meta-analysis of T2D in 17 GWAS comprising 8,284 cases and 15,543 controls 
in African Americans identified rs7003257, an intron variant in CPA6, as being associated with T2D 
(p=1.17x10-6)(40) and this SNP has also been previously reported to affect 2 hour glucose levels(41). We 
were underpowered to detect an association in black subjects. However, meta-analyzing all available 
black subjects in ACCORD, REP2, and REP3 improved the statistical power so an association was 
detectable (p=0.005). It will be necessary for additional studies to investigate the extent to which CPA6 
is involved with metformin drug response.   
A genotyped SNP in the NBEA gene on chr13, rs57081354, was associated with change in HbA1c 
levels at genome-wide significance (p=4.02x10-8, =0.323) in our discovery cohort (Figure 3). SNPs in 
NBEA did not replicate in REP1-3 cohorts. Rs57081354 was marginally associated with baseline HbA1c 
levels in individuals who were taking metformin at the time they enrolled in ACCORD, with the C-allele 
displaying higher HbA1c values (p=0.09) (Figure 3c). NBEA is a protein kinase A anchor protein that is 
expressed at low levels ubiquitously and at higher levels in the brain, pituitary, and beta cells in the 
pancreas(42). Interestingly, haplotype-insufficient Nbea(+/-) mice prefer sugary foods (glucose and 
fructose) more than their wild-type controls, gain more weight per unit of food than wild type mice, and 
have higher insulin and leptin levels(29). Subsequently, we tested for associations between rs57081354 
and 19 dietary scores recorded for a subset of 1553 ACCORD subjects and found that rs57081354 was 
associated with an increase in dessert consumption (q<0.2) in those with C-allele (Table S6). An 
expanded summary of the literature regarding NBEA can be found in the Supplementary Material.  
Additionally, we tested rare variants for associations with change in HbA1c, and STAT3 when all 
races were combined, was the only gene that achieved statistical significance for metformin treatment 
response (q<0.1). However, as described in the results, black subjects were the only population with 
rare variation in STAT3 and STAT3 was not detected in the stratified analysis likely due to the small 
number of subjects available for analysis (n=222).  In this same cohort, rare variants in STAT3 were not 
associated with baseline HbA1c levels(q>0.2). STAT3 encodes a ubiquitously expressed transcription 
factor with broad activities in metabolism, immunity, and cell growth(43). STAT3 is an essential signal 
transducer for the key metabolic hormone leptin and the pleiotropic cytokine interleukin 6 with broad 
effects on feeding behavior and fuel homeostasis. Interestingly, metformin has been shown to interact 
with STAT3 signaling in chemotherapeutic applications and in an inflammatory bowel disease model(44). 
To our knowledge, interactions between metformin and STAT3 signaling have not been investigated 
with regards to glucose homeostasis. 
Here we present evidence for PRPF31, CPA6, and STAT3 as being involved in novel glucose-lowering 
mechanisms for metformin. Additional investigation will also be required to confirm the clinical impact 
of the identified variants with regards to metformin therapy in diabetic subjects. Although prior studies 
suggest roles for NBEA and STAT3 genes in glucose metabolism, additional research will be required to 
investigate mechanisms by which they might interact with metformin. Such studies are likely to provide 
new insight into mechanisms regulating glucose metabolism and may point the way towards novel 
therapeutic targets for more precise interventions in T2D.   
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Tables 
Table 1. Cohort Demographics and Concomitant Medications 
 All Races 
Combined 
(N=1312) 
White Subjects 
Only (N=845) 
Black Subjects Only 
(N=222) 
Intensive glycemia arm (%) 56.33 59.41 53.15 
Standard glycemia arm (%) 43.67 40.59 46.85 
Intensive blood pressure arm 
(%) 
23.86 23.67 34.23 
Standard blood pressure arm 
(%) 
23.78 21.89 33.33 
Fibrate lipid treatment arm (%) 25.99 25.68 14.41 
Placebo lipid treatment arm 
(%) 
26.37 28.76 18.01 
Female (%) 39.48 36.33 52.70 
Age (mean [95% CI]) 62.72 [62.36-63.10] 63.14 [62.70-63.58] 62.25 [61.37-63.12] 
BMI (mean [95% CI]) 32.43 [32.13-32.73] 33.18 [32.82-33.54] 32.67 [31.94-33.39] 
Years with T2D (mean [95% CI]) 10.10 [9.67-10.51] 9.73 [9.23-10.24] 10.82 [9.76-11.87] 
History of cardiovascular 
disease (%) 
33.54 35.27 29.28 
Concomitant Medications* 
Angiotensin type 2 antagonists 
(%) 
16.39 15.98 16.67 
Ace inhibitors (%) 46.19 46.98 52.25 
Alpha-glucosidase inhibitors 
(%) 
0.53 0.47 0.45 
Cholesterol absorption 
inhibitors (%) 
2.13 2.49 1.80 
Statin (%) 49.70 51.83 30.18 
Lisinopril (%) 16.46 16.45 25.23 
Loop diuretics (%) 8.23 8.99 10.36 
Meglitinides (%) 2.97 2.37 3.15 
Nitrates (%) 5.72 6.51 3.60 
Other Diabetes Treatments (%) 2.67 2.84 4.05 
Sulfonylureas (%) 52.44 51.83 45.05 
Thiazolidinediones (%) 31.63 33.02 29.28 
Insulin (%) 38.11 38.11 45.95 
*Tabulated percentages represent the percentage of subjects with at least one record of taking the 
medication, or a medication in the drug class, during the metformin treatment window. This is not an 
exhaustive list of medications recorded in ACCORD, rather a representative list of the commonly used 
medications in ACCORD.  
 
Table 1. Lead SNPs Associated with HbA1c response in Common Variant Analysis in All Races 
Combined (p < 5x10-6) 
SNP Chromosome Position Gene Type MAF Beta P Value 
rs7371352 2 205916609 NA IMPU 0.461 0.166 1.29E-06 
rs12694529 2 220685415 NA META 0.131 0.232 1.06E-06 
rs2371651 3 64899735 ADAMTS9-AS2 IMPU 0.346 0.171 4.89E-06 
rs36050186 3 73884807 LOC105377165 IMPU 0.061 0.315 4.46E-06 
rs28535480 3 144238665 LOC105374140 IMPU 0.447 0.184 4.12E-07 
rs7669299 4 77525989 CXCL13 GENO 0.106 -0.348 5.88E-07 
rs79827403 4 140248372 NA IMPU 0.046 -0.386 2.19E-06 
rs6884548 5 104706194 LOC105379109 IMPU 0.038 0.439 2.64E-06 
rs56061109 5 113100738 MCC IMPU 0.048 0.394 6.00E-07 
rs6903843 6 3125135 BPHL IMPU 0.031 0.587 3.36E-06 
rs79573377 6 91226278 NA IMPU 0.033 0.437 3.19E-06 
rs59506474 6 136927217 NA IMPU 0.066 -0.355 1.57E-06 
rs2578120 10 78453110 NA IMPU 0.358 -0.160 2.53E-06 
rs7307035 12 53778761 LOC107984525 META 0.033 -0.440 1.77E-06 
rs12300320 12 93077216 LOC643339 IMPU 0.053 -0.386 3.01E-06 
rs12827634 12 95026750 NR2C1 IMPU 0.362 0.154 3.18E-06 
rs57081354 13 35202456 NBEA GENO 0.077 0.326 4.02E-08 
rs4144603 14 96729576 NA META 0.405 0.159 1.36E-06 
rs7173199 15 29424654 FAM189A1 IMPU 0.046 0.419 1.77E-06 
rs182384419 15 79438983 KIAA1024 IMPU 0.043 0.394 2.66E-06 
rs74007109 16 6852072 RBFOX1 IMPU 0.040 0.407 2.92E-06 
rs2529698 17 12350355 NA META 0.061 0.331 9.24E-07 
rs254271 19 54630757 PRPF31 IMPU 0.330 0.163 3.79E-06 
rs6139020 20 3156571 UBOX5 IMPU 0.102 0.257 3.08E-06 
 
  
  
Table 2. Lead SNPs Associated with HbA1c response in Common Variant Analysis in White 
Subjects Only (p < 5x10-6) 
SNP Chromosome Position Gene Type MAF Beta P Value 
rs12047072 1 97401162 DPYD META 0.184 -0.215 4.66E-06 
rs13034779 2 234091216 NA IMPU 0.305 0.239 6.24E-07 
rs2371651 3 64899735 ADAMTS9-AS2 IMPU 0.431 0.192 3.71E-06 
rs36050186 3 73884807 LOC105377165 IMPU 0.082 0.332 2.47E-06 
rs71140472 3 144248959 NA IMPU 0.461 0.177 3.30E-06 
rs2929535 8 67754375  CPA6a META 0.307 -0.188 3.47E-06 
rs111976192 8 83716899 NA IMPU 0.267 0.195 4.99E-06 
rs10904150 10 3970713 NA IMPU 0.072 -0.336 4.66E-06 
rs4567482 11 134474052 LOC283177 META 0.123 -0.286 1.66E-07 
rs7298631 12 95063515 NR2C1 IMPU 0.397 0.176 4.51E-06 
rs4775474 15 62150069 NA META 0.355 0.189 2.07E-06 
rs182384419 15 79438983 KIAA1024 IMPU 0.054 0.503 1.53E-08 
a rs2929535 does not fall in CPA6, but rs2162145 (p=4.04x10-6) is in the same peak and is 
located in CPA6. 
  
Table 3. Lead SNPs Associated with HbA1c response in Common Variant Analysis in Black 
Subjects Only (p < 5x10-6) 
SNP Chromosome Position Gene Type MAF Beta P Value 
rs7573365 2 183278246 NA META 0.325 -0.379 3.67E-06 
rs12496540 3 32062976 NA IMPU 0.352 0.388 4.98E-06 
rs62284968 3 197429996 LOC105374308 IMPU 0.040 1.066 1.20E-07 
rs9295608 6 23977533 NA GENO 0.208 -0.462 1.35E-06 
rs111792250 6 136927930 SLC35D3a IMPU 0.192 -0.528 7.97E-07 
rs4413694 7 142430649 NA IMPU 0.458 -0.346 4.43E-06 
rs201739756 8 73149128 NA IMPU 0.054 0.875 2.04E-06 
rs145554029 8 77485920 LOC102724874b IMPU 0.035 -1.221 8.76E-09 
rs10897557 11 80135250 LOC105369406 IMPU 0.319 -0.432 6.73E-07 
rs7130041 11 128552747 ETS1 IMPU 0.348 -0.406 3.02E-06 
rs76853142 13 93580057 GPC6 IMPU 0.041 -0.940 4.54E-06 
rs1449836 14 42994192 NA META 0.471 -0.353 1.43E-06 
rs62072150 17 73412120 SDK2 IMPU 0.451 -0.423 4.12E-06 
rs185341538 19 32981426 RHPN2 IMPU 0.291 -0.428 2.99E-06 
rs34600526 19 33504770 NA IMPU 0.295 -0.395 4.49E-06 
ars111792250 does not fall in SLC35D3, but rs7763578 (p=1.47x10-6) is in the same peak and is located in 
SLC35D3. b rs145554029 does not fall in LOC102724874, but rs75121529 (p=1.22x10-8) is in the same 
peak and is located in LOC102724874.  
 
  
Figure Legends 
Figure 1. Study design and quality control workflow. Boxes represent the step taken in the workflow. 
The number of remaining subjects after a quality control step can be found in the relevant attached 
circle.  
Figure 2. Distributions of HbA1c response to metformin treatment. A) HbA1c response when all races 
are combined. B) HbA1c response in only white participants. C) HbA1c response in only black 
participants. 
Figure 3. HbA1C response to metformin treatment is diminished by SNPs in NBEA. A) Manhattan plot 
of HbA1c response to metformin treatment when all races were combined (N=1312). The horizontal 
dashed lines represent suggestive statistical significance (p=5x10-6) and genome-wide significance 
(p=5x10-8). Each point represents a single SNP. Genotyped SNPs are represented with black dots, 
imputed SNPs are represented by blue dots, and SNPs meta-analyzed from subjects genotyped in Set 1 
subjects and imputed in Set 2 subjects are represented by pink dots. B) A LocusZoom (48) plot 
demonstrating the lead SNP, rs57081354, association with change in HbA1c when all races are 
combined. Linkage disequilibrium was calculated using the 1000 genomes reference panel using the 
hg19/1000 Genomes Nov 2014 EUR selection, matching the panel used to perform imputation in 
ACCORD. C) Forest plot demonstrating associations of rs57081354 in available replication cohorts. The 
beta values for REP1 were changed to the additive inverse to maintain a consistent direction of effect. A 
larger beta value means a diminished metformin response. Data for rs57081354 were not available for 
REP2 and REP3Bars represent the 95% confidence interval.  D) Change in HbA1c by rs57081354 
genotype as represented by violin plots. 
Figure 4. Forest plot of associations with replicated SNPs in REP1, REP2, and REP3. A) Discovery and 
replication results for rs2162145, located in the CPA6 gene. B) Discovery and replication results for 
rs254271, an intronic variant in PRPF31. A larger beta value means a diminished metformin response. 
The beta values for REP1 were changed to the additive inverse to maintain a consistent direction of 
effect. Bars represent the 95% confidence interval. 
 
